China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062) 영업이익률

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.

연도	영업이익률	변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.

연도

영업이익률

변화

제공된 날짜에 대한 데이터가 충분하지 않습니다.

회사	영업이익률	영업이익률 차이	국가
MERCK Kommanditgesellschaft auf Aktien MER.SW	0.00%	-	DE
Merck KGaA MRK.DE	0.00%	-	DE
Takeda Pharmaceutical Company Limited 4502.T	0.00%	-	JP
Galderma Group AG GALD.SW	0.00%	-	CH
Sun Pharmaceutical Industries Limited SUNPHARMA.NS	22.93%	-	IN

회사

영업이익률

영업이익률 차이

국가